Verified Clinical Trials is utilized by the great majority of North American phase 1 centers to prevent duplicate enrollment in clinical trials. Verified Clinical Trials has also garnered significant late phase uptake in various therapeutic indications. This allows a pharmaceutical sponsor to protect and follow their investigational product from phase 1 through it’s clinical trials development. The advantages are obvious. In particular, Verified Clinical Trials has the ability to exclude research subjects from enrolling in research trials if there exists a need for the subject to be anise to the compound.
The incidence of duplicate enrollment attempts from therapeutic indications to “healthy volunteers” is disturbing but not entirely surprising. Verified Clinical Trials is the only method of preventing these occurrences. The professional research subject or guinea pig has been referenced in many articles including this piece in The Atlantic
Verified Clinical Trials has consistently grown it’s uptake. The NIH is currently employing Verified Clinical Trials services.
Phase 1 clinical trial research is well aware of the issues as well as Verified Clinical Trials as evidenced by many of the JALR (Just another lab rat) blogs.